drugset / Trial / NCT01283789
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
Phase 2
Unknown
23 enrolled
University of Kansas Medical Center
GlaxoSmithKline · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
By doing this study, researchers hope to learn the effectiveness of the combination of Lapatinib and RAD-001 for treating patients who have progressed on previous therapies.
Timeline
- Start
- 2011-02
- Primary completion
- 2016-04
- Completion
- 2017-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |